RT Journal Article
SR Electronic
T1 Late Breaking Abstract - CPAnet Registry – An International Chronic Pulmonary Aspergillosis Registry
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4929
DO 10.1183/13993003.congress-2020.4929
VO 56
IS suppl 64
A1 Eva Van Braeckel
A1 Lander Van Acker
A1 Helmut J.F. Salzer
A1 Danila Seidel
A1 Oliver A. Cornely
A1 Martin Hoenigl
A1 Ana Alastruey-Izquierdo
A1 Christophe Hennequin
A1 Cendrine Godet
A1 Aleksandra Barac
A1 Holger Flick
A1 Oxana Munteanu
A1 Christian B. Laursen
A1 Jesper Rømhild Davidsen
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/4929.abstract
AB Background: Chronic pulmonary aspergillosis (CPA) is a chronic fungal infection of the lung associated with high morbidity and mortality. The CPAnet registry established in 2018 is an international multicenter collaboration aiming to improve CPA knowledge and patient care. In 2020, it has been awarded a Clinical Research Collaboration (CRC) by the ERS. This study’s aim was to describe the data collection process and content of CPAnet registry, by presenting preliminary clinical data.Methods: In the CPAnet registry, clinical data are collected through a web-based questionnaire. Data include CPA phenotype, comorbidities, treatment, outcome and follow-up from several international centers. An exemplary descriptive analysis was performed on 74 patients, who were registered online before April 2020.Results: CPA patients were predominantly (72%) male, 39% had chronic obstructive pulmonary disease and 68% had a history of smoking. Chronic cavitary pulmonary aspergillosis was the most common CPA subtype (62%). In 32 patients (52%), voriconazole was the preferred first-line therapy.Conclusion: The multicenter multinational CPAnet registry is a valuable approach to gather comprehensive data on a large study population and reflects real-world clinical practice rather than focusing on specific patient populations in more specialized centers. Additional CPA reference centers are being encouraged to join this promising CRC.* The 2 first (EVB and LVA) and 2 last authors (CBL and JRD) contributed equally.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4929.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).